UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 28, 2014

 

 

Dendreon Corporation

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-35546   22-3203193

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1301 2nd Avenue, Seattle, Washington   98101
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (206) 256-4545

Not applicable.

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(c) (d) Effective July 28, 2014, the board of directors of Dendreon Corporation (the “Company”) appointed W. Thomas Amick to serve as President and Chief Executive Officer of the Company and a member of the Company’s board of directors. Mr. Amick succeeds John H. Johnson, who will serve as CEO Emeritus of the Company until August 15, 2014, in accordance with the terms of his Transition and Separation Agreement.

In connection with his appointment as President and Chief Executive Officer of the Company, Mr. Amick entered into an Executive Employment Agreement with the Company, dated July 28, 2014 (the “Agreement”).

The Agreement provides for an annual base salary of approximately $600,000, and eligibility for a performance-based annual bonus subject to the achievement of specified targets agreed upon in advance by the Board, with a target bonus equal to 67% of his annual base salary (subject to pro-ration for 2014). The agreement provides for a one-time sign-on bonus of $100,000, to be paid as soon as practicable following July 28, 2014 but no later than the tenth day of employment with the Company. The Agreement also provides for the following equity grants: (1) a restricted stock award of 125,000 shares of the Company’s common stock, which award will vest as to 25% of the shares underlying the award on the first anniversary of the date Mr. Amick commences employment with the Company and thereafter at a rate of 1/12 of the total remaining number of shares in equal quarterly installments (in each case, subject to continued employment); and (2) a restricted stock award of 125,000 shares of the Company’s common stock, which award will vest over no more than a three year period based on the achievement of certain performance criteria determined by the Board. Mr. Amick will also be eligible to receive annual grants of stock options, restricted stock and other equity-based long-term incentive compensation generally made available to comparable senior executives of the Company on substantially the same terms and conditions as generally applicable to such other executives.

The Agreement has no specified term and may be terminated by Mr. Amick or by the Company at any time. The Agreement provides that if, on or prior to the first anniversary of the effective date of the Agreement, the Company terminates Mr. Amick’s employment without Cause, or if he resigns for Good Reason (each as defined in the Agreement), Mr. Amick will be entitled to a lump sum severance payment equal to the sum of three months of his then current base salary plus an additional one month of his then current base salary for each full month of service completed. The Agreement further provides that if Mr. Amick experiences such a termination following the first anniversary date of the Agreement, he will be entitled to a lump sum severance payment equal to the sum of 125% of his then current base salary plus 125% of his target annual bonus for such year. If after the first anniversary of the Agreement such a termination occurs within three months before, or twelve months after, a Change of Control of the Company (as defined in the Agreement), then Mr. Amick will be entitled to the sum of 150% of his then current base salary plus 150% of his target annual bonus for such year. In either case, and in the case of death or termination due to disability, he will also be entitled to full accelerated vesting of any unvested stock options and any unvested restricted stock held by him. In addition, in either case, he will be entitled to continuation of certain welfare benefits and outplacement services and moving expenses of up to $10,000. The Agreement requires that Mr. Amick not compete with the Company during the term of his employment and for a period of nine months after termination of his employment and also requires that Mr. Amick not solicit the Company’s customers or employees after termination of his employment for a period of one year. The Company has agreed to reimburse Mr. Amick for legal fees of up to $15,000 relating to the preparation of the Agreement.

The foregoing description of Mr. Amick’s Executive Employment Agreement is qualified in its entirety by reference to the Agreement itself, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Mr. Amick, age 71, has been retired since 2013. Prior to that time, he served as the Chairman and Chief Executive Officer of Discovery Laboratories, Inc., a specialty biotechnology company, from October 2010 to December 2012. From March 2005 to October 2010, Mr. Amick served as the Chairman and Chief Executive Officer of Aldagen, Inc., a privately-held life sciences company. Prior to that time, Mr. Amick held various positions of increasing responsibility during his 30-year career with Johnson & Johnson, including Vice President of the Ortho Biotech Oncology Franchise, President of Janssen-Ortho, Inc., President of Ortho Biotech Europe, and Vice President of J&J Development Corporation. Mr. Amick holds a B.S. degree in business administration from Elon University.

There are no arrangements or understandings between Mr. Amick and any other persons pursuant to which he was appointed as a director and President and Chief Executive Officer of the Company. There are no family relationships between Mr. Amick and any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer. No information is required to be disclosed with respect to Mr. Amick pursuant to Item 404(a) of Regulation S-K.

The full text of the Company’s press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

10.1    Executive Employment Agreement, dated July 28, 2014.
99.1    Dendreon Corporation press release dated July 30, 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      DENDREON CORPORATION
Date: July 30, 2014      

/s/ Robert L. Crotty

Robert L. Crotty

Executive Vice President, General Counsel and Secretary

EXHIBIT INDEX

 

Exhibit No.

   

Description

10.1    Executive Employment Agreement, dated July 28, 2014.
99.1    Dendreon Corporation press release dated July 30, 2014.


Exhibit 10.1

DENDREON CORPORATION

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (this “Agreement”) is effective as of July 28, 2014 (“Effective Date”), by and between Dendreon Corporation, a Delaware corporation (the “Company”), and W. Thomas Amick (“Employee”).

The parties agree as follows:

1. Employment. The Company hereby employs Employee as Chief Executive Officer, and Employee hereby accepts such employment, upon the terms and conditions set forth in this Agreement.

2. Duties.

2.1 Position. Employee shall perform such duties as are customary for the position of Chief Executive Officer at companies of the Company’s size and nature in the United States and any additional duties that the Board of Directors of the Company (the “Board”) may reasonably prescribe from time to time and which are consistent with Employee’s position. Employee shall devote Employee’s full business time and efforts to the performance of Employee’s assigned duties for the Company, provided, however, that Employee may devote reasonable periods of time to (a) serving on the board of directors of other corporations subject to the prior approval of the Board and (b) engaging in charitable or community service activities, so long as none of the foregoing additional activities materially interfere with Employee’s duties under this Agreement. As soon as practicable following the Effective Date, Employee shall be appointed as a member of the Board.

2.2 Work Location. Employee’s principal place of work shall be located in Bridgewater, NJ, or such other location as the parties may agree upon from time to time.

3. Term. The employment relationship pursuant to this Agreement shall begin on the Effective Date, will be for no specified term, and may be terminated by Employee or the Company at any time, with or without Good Reason or Cause (as defined in Section 6), as applicable, subject to the provisions regarding termination set forth in Section 6.

4. Compensation.

4.1 Base Salary. As compensation for Employee’s performance of his duties under this Agreement, the Company shall pay Employee a base salary (“Base Salary”), which shall initially equal six hundred thousand dollars and 18 cents ($600,000.18) per calendar year, payable in accordance with the normal payroll practices of the Company, less required deductions for state and federal withholding tax, social security and all other required employment taxes and payroll deductions. For purposes of Section 6 hereof, Employee’s Base Salary shall be the current Base Salary as of the date of his termination of employment (the “Termination Date”). The Base Salary may not be reduced unless the base salaries of all other employees of the Company at the Vice President level and above are proportionally reduced and in the case of such reduction, Base Salary shall not be reduced by more than 10%.

4.2 Incentive Compensation. Within thirty (30) days after the end of each calendar year, if the Company and Employee meet specified targets agreed upon in advance by the Board, Employee shall be entitled to receive a target bonus of sixty seven percent (67%) of the Base Salary (the “Annual Bonus”) as determined by the Board, in its sole discretion such amount to be pro-rated for the remainder of the 2014 calendar year. Employee must be currently employed by the Company as of the date of payment of any Annual Bonus in order to be entitled to such payment. If the Company and Employee do not fully meet such targets, the Company may pay Employee a bonus of such amount as the Board deems appropriate in its sole discretion. Before the beginning of a new bonus year, the Board may, in its discretion, reduce the percentage of the Annual Bonus applicable to Employee, provided that Employee’s Annual Bonus may be reduced only to the extent that the percentage annual bonuses of all other employees of the Company at the Vice President level and above are proportionally reduced.

4.3 Equity Grants. The Company shall grant to the Employee on the last business day of the month in which the Effective Date occurs the following long-term incentive awards:

(a) Time-Based Restricted Shares. A restricted stock award of 125,000 shares of the Company’s common stock. Such award shall vest as to 31,250 of the shares underlying the award on the first anniversary of the date Employee commences employment with the Company and with respect to an additional 7,813 shares upon the last day of each calendar quarter following such first anniversary until fully vested, provided that the Employee is employed by the Company or its affiliate on the applicable vesting date. The other terms and conditions of such award shall be set forth in the applicable award agreement.

(b) Performance-Based Restricted Shares. A restricted stock award of 125,000 shares of the Company’s common stock. Such award shall vest and become exercisable upon the satisfaction of the performance conditions (based upon a performance period of no greater than 3 years) to be determined by the Board. The other terms and conditions of such award shall be set forth in the applicable award agreement.

(c) Interpretation. In the event of a conflict between the terms of this Agreement and the terms of the award agreements referenced in Sections 4.3(a) and 4.3(b) above, the terms of this Agreement shall govern.

4.4 Sign-On Bonus. As soon as practicable following the Effective Date, but not later than the tenth 10th day following the day Employee commences employment with the Company, the Company shall pay Employee a one-time sign-on bonus in the amount of one hundred thousand dollars $100,000, subject to all applicable withholdings and deductions, subject to Employee’s employment with the Company on such date.

4.5 Equity Grants. Employee shall be eligible to receive annual grants of stock options, restricted stock and other equity based long term incentive compensation generally made available to comparable senior executives of the Company on substantially the same terms and conditions as generally applicable to such other executives.

 

- 2 -

4.6 Performance and Compensation Review. Employee’s performance will be reviewed no less frequently than annually to determine whether Employee’s salary or other compensation should be modified.

4.7 Vacation. Employee shall be eligible to earn four (4) calendar weeks of paid vacation in each year of this Agreement. Vacation will accrue at the rate of six and two-thirds (6 2/3) hours per pay period, and may be carried over from year to year up to a maximum cap of 240 hours and in accordance with Company policy. Additional paid vacation shall accrue in accordance with Company policy. Any accrued unused vacation will be cashed out upon termination of employment at Employee’s then current Base Salary rate in accordance with Company policy and applicable law.

4.8 Benefits and Insurance. In addition to the vacation benefits in Section 4.6 above, Employee shall be entitled to all benefits that the Company may make generally available from time to time to its employees, subject to the terms and conditions of the applicable policy or plan, and provided that Employee understands that he/she will be designated as a key employee for purposes of any leave granted under the Family and Medical Leave Act.

5. Business Expenses. The Company shall pay, or promptly reimburse, Employee for all reasonable, out-of-pocket travel and business expenses incurred in the performance of Employee’s duties on behalf of the Company for which Employee submits the required supporting documentation and otherwise fully complies with the Company’s travel and expense reimbursement policy as in effect from time to time. Reimbursements under this Section 5 will be made in accordance with Section 9.12.

6. Separation of Employee’s Employment.

6.1 Termination for Cause by the Company. The Company may terminate Employee’s employment at any time for Cause. For purposes of this Agreement, “Cause” is defined as: (i) Employee’s willful and continued failure to substantially perform his duties and responsibilities, after prior written notice thereof and an opportunity to cure; (ii) Employee’s willful engaging in conduct which is materially injurious (monetarily or otherwise) to the Company, including without limitation, misuse of Company funds or property; (iii) Employee’s conviction of a felony (other than a moving vehicle violation); or (iv) any other material breach by Employee of this Agreement or any confidentiality, noncompetition, nondisclosure and/or invention agreement with the Company which is materially injurious (monetarily or otherwise) to the Company. Notwithstanding the foregoing, the Company must notify Employee of any event constituting Cause within 45 days following the Company’s knowledge of its existence or such event will not constitute Cause under this Agreement. For purposes of this Agreement, no act or failure to act, on the part of Employee, will be considered “willful” unless it is done, or omitted to be done, by Employee in bad faith or without reasonable belief that Employee’s action or omission was in the best interests of the Company. Employee’s employment will in no event be considered to have been terminated by the Company for Cause if the act or failure to act upon which such termination is based is an act or failure to act in respect of which Employee meets the applicable standard of conduct prescribed for indemnification or reimbursement or payment of expenses under the Company’s Amended and Restated Bylaws or the laws of the state of its incorporation or the directors’ and officers’ liability insurance of the Company, in each case as in effect at the time of such act or failure to act.

 

- 3 -

In the event that Employee’s employment is terminated in accordance with this Section 6.1, Employee shall be entitled to receive, on Employee’s first regular payday following the Termination Date, a lump sum payment equal to the following: (i) any portion of Employee’s Base Salary that has been earned but not yet paid as of the Termination Date, and (ii) any accrued unused vacation as of the Termination Date, all of the foregoing to be less required withholding (clauses (i) and (ii) collectively, the “Accrued Benefits”). All other Company obligations to Employee, including but not limited to any bonus as described in Section 4.2 and Severance (as defined in Section 6.2), will automatically terminate and be completely extinguished as of the Termination Date; provided, however, Employee shall continue to be entitled to any accrued benefits under the Company’s benefit and welfare plans and to indemnification and continued coverage under the Company’s director and officer insurance policies (“D&O Policies”) as well as the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.

6.2 Termination Without Cause; Change of Control.

(a) If, on or prior to the first anniversary of the Effective Date (whether or not there has been or may in the future be a Change of Control), the Company terminates Employee’s employment without Cause, or if Employee resigns for Good Reason in accordance with Section 6.3, then Employee will be entitled to receive the following:

(i) a lump sum severance payment in an amount equal to the sum of (A) three months of Employee’s then current Base Salary (without regard to any reduction in Base Salary that would otherwise constitute Good Reason) plus (B) an additional one month of Employee’s then current Base Salary (without regard to any reduction in Base Salary that would otherwise constitute Good Reason) for each full month of Employee’s service completed following the Effective Date at the time of such termination (all subject to required withholding), and (ii) the amounts set forth in paragraph (d) below.

(b) If, following the first anniversary of the Effective Date, the Company terminates Employee’s employment without Cause, or if Employee resigns for Good Reason in accordance with Section 6.3, then Employee will be entitled to receive the following:

(i) a lump sum severance payment in an amount equal to one hundred twenty five percent (1.25x) of the sum of Employee’s then current Base Salary (without regard to any reduction in Base Salary that would otherwise constitute Good Reason) and Employee’s target Annual Bonus in respect of the calendar year in which the termination of employment occurs, less required withholding, and (ii) the amounts set forth in paragraph (d) below.

(c) If, following the first anniversary of the Effective Date, the Company terminates Employee without Cause, or if Employee resigns for Good Reason in accordance with Section 6.3, in either case within three (3) months before or twelve (12) months following a Change of Control, then, in lieu of the payment provided under Section 6.2(b), Employee will be entitled to receive, the following (the “CIC Severance Payment”):

 

- 4 -

(i) a lump sum severance payment in an amount equal to one hundred fifty percent (1.5x) of the sum of Employee’s then current Base Salary (without regard to any reduction in Base Salary that would otherwise constitute Good Reason) and Employee’s target Annual Bonus in respect of the calendar year in which the termination of employment occurs; and (ii) the amounts set forth in paragraph (d) below.

(d) In addition to those amounts set forth in paragraphs (a), (b) or (c) above, as applicable, Employee shall be entitled to (i) on Employee’s first regular payday following the Termination Date, a lump sum payment equivalent to the Accrued Benefits; (ii) reasonable costs not to exceed $10,000 for outplacement services provided by a purveyor approved by the Company and moving expenses, upon delivery to the Company of an itemized invoice for such services provided that, in each case, such costs are incurred within six (6) months of the Termination Date; (iii) a lump sum payment in an amount equal (on an after-tax basis) to Employee’s cost (determined as of the Termination Date) to purchase continuation of all medical and dental benefits in effect on the Termination Date for a period of eighteen (18) months following the Termination Date pursuant to Employee’s right to elect continuation of group health plan benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985; (iv) any unpaid Annual Bonus with respect to the calendar year ended prior to the termination of Employee’s employment; and (v) full accelerated vesting of any and all unvested stock options, restricted stock units and restricted stock grants held by Employee.

(e) “Change of Control” shall mean the occurrence, in a single transaction or in a series of related transactions, of one or more of the following events:

(i) Any Person, as defined under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Person”), becomes the owner of voting securities of the Company (“Voting Securities”) representing more than fifty percent (50%) of the combined voting power of the Company’s then-outstanding securities, other than by virtue of a merger, consolidation or similar transaction; provided, however, that in determining whether a Change of Control has occurred, Voting Securities which are acquired by any Person in a Non-Control Acquisition (as hereinafter defined) shall not constitute an acquisition which would cause a Change of Control. A “Non-Control Acquisition” shall mean an acquisition by (A) an employee benefit plan (or a trust forming a part thereof) maintained by (1) the Company or (2) any of the Company’s subsidiaries, (B) the Company or any of the Company’s subsidiaries, or (C) any Person of not more than 25% of the Voting Securities that is entitled to and does report such beneficial ownership on Schedule 13G under the Exchange Act (a “13G Filer”), provided, however, that this clause (C) shall cease to apply when a Person who is a 13G Filer becomes required to file a Schedule 13D under the Exchange Act with respect to such beneficial ownership of the Voting Securities;

(ii) The consummation of a merger, consolidation or similar transaction that directly or indirectly involves the Company (a “transaction”), other than a transaction which results in (A) the Incumbent Directors (as hereinafter defined) constituting immediately after such transaction at least a majority of the Board, the entity surviving such

 

- 5 -

merger or consolidation or, if the Company or the entity surviving such merger is then a subsidiary, the ultimate parent thereof, and (B) the voting securities of the Company outstanding immediately prior to such transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any subsidiary of the Company, more than fifty percent (50%) of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such transaction;

(iii) The stockholders of the Company approve, or the Board approves, a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company otherwise occurs;

(iv) The consummation of a sale, lease or other disposition of all or substantially all of the consolidated assets of the Company (a “disposition”) that requires approval of the Company’s stockholders under Delaware corporate law; provided that this paragraph (d)(iv) excludes a disposition to an entity with respect to which stockholders of the Company own immediately after the disposition more than fifty percent (50%) of the combined voting power of the entity’s outstanding voting securities; or

(v) The Board ceases to be composed of at least a majority of Incumbent Directors. “Incumbent Directors” are the current members of the Board and any subsequent Board member who was nominated or elected by a majority vote of the Incumbent Directors then in office; provided, however, that no individual shall be considered an Incumbent Director if such individual initially assumed office as a result of either an actual or threatened election contest or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board (a “Proxy Contest”) including by reason of any agreement intended to avoid or settle any election contest or Proxy Contest.

Notwithstanding the above clauses (i) through (v), a “Change of Control” shall not have occurred (unless the Board determines otherwise) by reason of either of the following: (A) any corporate reorganization, merger, consolidation, transfer of assets, liquidating distribution or other transaction entered into solely by and between the Company and any subsidiary of the Company (a “reorganization”), provided the reorganization was approved by at least two-thirds (2/3) of the Incumbent Directors (as defined above) then in office and voting; or (B) any of the transactions described in clauses (i) through (v) above occurs pursuant to an Insolvency Proceeding. An “Insolvency Proceeding” means (A) the Company institutes or consents to the institution of any proceeding under any debtor relief law, makes an assignment for the benefit of creditors, or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for the Company or for all or any material part of the Company’s property; or (B) any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of the Company and the appointment continues undischarged or unstayed for 60 calendar days; or (C) any proceeding under any debtor relief law relating to the Company or to all or any material part of the Company’s property is instituted without the consent of the Company and continues undismissed or unstayed for 60 calendar days, or any order for relief is entered in any such proceeding.

 

- 6 -

(f) The payments and benefits to which Employee is entitled under Section 6.2(a), Section 6.2(b), Section 6.2(c) and Section 6.2(d) are referred to as “Severance.” All other Company obligations to Employee pursuant to this Agreement other than Employee’s accrued benefits under the Company’s benefit and welfare plans and his rights to indemnification and continued coverage under the Company’s D&O Policies and indemnification rights under the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws will automatically terminate and be completely extinguished as of the Termination Date.

6.3 Resignation of Employee for Good Reason.

(a) Other than during the twelve (12) month period commencing on the date of a Change of Control (such twelve (12) month period, the “Change of Control Protection Period”), Employee may resign for “Good Reason” upon notice to the Company within thirty (30) days following the relevant event or condition if any of the following occurs without Employee’s express consent, the Company fails to cure such breach within twenty (20 days) after its receipt of such notice, and Employee’s termination for Good Reason occurs within thirty (30) days after the end of such cure period:

(i) The Board or Company (A) alters Employee’s duties, responsibilities or title resulting in a significant diminution of Employee’s position, duties, responsibilities or status with the Company or, (B) requires Employee to report to anyone other than the Board or (C) a material reduction in Employee’s Base Salary (which means a reduction in Base Salary that is not in accordance with Section 4.1 above);

(ii) The Board or Company transfers or assigns Employee to any location that is more than fifty (50) miles from the location of Employee’s principal office. Required travel on the Company’s business that is consistent with the business travel obligations of Employee’s position is excluded from this Section 6.3(a)(ii); or

(iii) The Company materially breaches its obligations under this Agreement.

(b) During the Change of Control Protection Period, Employee may resign for “Good Reason” upon notice to the Company within thirty (30) days following the relevant event or condition if any of the following occurs without Employee’s express consent and the Company fails to cure such breach within 20 days after its receipt of such notice:

(i) A material adverse change in Employee’s duties, responsibilities or title as in effect at any time within one year preceding the date of a Change of Control or at any time thereafter; the assignment to Employee of any duties or responsibilities which are inconsistent with his duties, responsibilities or title as in effect at any time within one year preceding the date of a Change of Control or at any time thereafter; or any removal of Employee from or failure to reappoint or reelect him to any of such offices or positions, except in connection with the termination of his employment for Disability, Cause, as a result of his death or by Employee other than for Good Reason;

 

- 7 -

(ii) A material reduction in Employee’s Base Salary or target annual bonus opportunity as in effect at any time within one year preceding the date of a Change of Control or at any time thereafter (which means a reduction in Base Salary or target annual bonus opportunity that is not in accordance with Section 4.1 or 4.2 above, as applicable);

(iii) The Board or Company transfers or assigns Employee to any location that is more than fifty (50) miles from the location of Employee’s principal office prior to the Change of Control. Required travel on the Company’s business that is consistent with the business travel obligations of Employee’s position is excluded from this Section 6.3(b)(iii);

(iv) The failure by the Company to (A) provide Employee with compensation and benefits, in the aggregate, at least equal (in terms of benefit levels and/or reward opportunities) to those provided for under a material employee benefit plan, program and practice in which Employee was participating at any time within one year preceding the date of a Change of Control or at any time thereafter, or (B) permit Employee to participate in any or all incentive, savings, retirement plans and benefit plans, fringe benefits, practices, policies and programs applicable generally to other similarly situated employees of the Company and affiliated companies of the Company (including any successors to the Company and affiliated companies of the Company);

(v) The Company materially breaches its obligations under this Agreement;

(vi) Any purported termination of Employee’s employment for Cause by the Company which does not comply with the terms of Section 6.1; or

(vii) The failure of the Company to obtain an agreement from any successors and to assume and agree to perform this Agreement.

6.4 Resignation by Employee Without Good Reason. Employee may voluntarily resign position with the Company without Good Reason at any time on thirty (30) days’ advance written notice. In the event Employee’s resignation is without Good Reason, Employee will be entitled to receive, on Employee’s first regular payday following the Termination Date, a lump sum payment equivalent to the Accrued Benefits. All other Company obligations to Employee pursuant to this Agreement other than Employee’s accrued benefits under the Company’s benefit and welfare plans and his rights to indemnification and continued coverage under the Company’s D&O Policies and indemnification rights under the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws will automatically terminate and be completely extinguished.

6.5 Employee’s Execution of Release and Timing of Payments.

(a) Release. Notwithstanding the foregoing, as a condition to the payment of any Severance, Employee will be required to execute, deliver and not revoke, within 60 days following the Termination Date, a release provided by the Company which contains a full and general release of claims in favor of the Company and its affiliates, which release shall

 

- 8 -

not include a waiver of Employee’s Accrued Benefits under the Company’s benefit and welfare plans or his rights to indemnification and continued coverage under the D&O Policies and indemnification rights under the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws (such release, substantially in the form attached hereto as Exhibit A, the “Release”). If the Release has not been executed, delivered and become irrevocable by Employee within the statutory revocation period, no payments of Severance, will be or become payable.

(b) Time of Payments. Unless otherwise stated and subject to Sections 6.5(a) and 9.12 hereof, all payments and reimbursements required to be made under this Section 6 to Employee (including any payments or reimbursements to which Employee is entitled in respect of the period commencing on the Termination Date and ending on the 60th day following the Termination Date) shall be made or shall commence on the 60th day following the Termination Date; provided, however, all payments required to be made under Section 6.2(c) to Employee shall be made or shall commence on the 60th day following the later of: (i) the Termination Date and (ii) the date of the Change in Control.

6.6 Termination Upon Death or Disability.

(a) Death. Employee’s employment will terminate automatically upon death of Employee. In the event of Employee’s death, the Accrued Benefits shall be paid, on Employee’s first regular payday following the Termination Date, to the beneficiary designated in writing by Employee (“Beneficiary”) or, if no such Beneficiary is designated, to Employee’s estate. In addition, (i) commencing on the Termination Date, the Company will continue Employee’s Base Salary until the earlier of six months from the Termination Date or the commencement of death benefits under any existing Company Group Life Insurance Plan, (ii) within sixty (60) days following the Termination Date, the Company shall pay any unpaid Annual Bonus with respect to the calendar year ended prior to the termination of Employee’s employment and a pro rata Annual Bonus (based upon his target Annual Bonus) for the year in which the termination of employment occurs; (iii) the Company shall fully accelerate vesting of any and all unvested stock options, restricted stock units and restricted stock grants held by Employee; and (iv) the Company shall continue the Employee’s right to indemnification and coverage under the D&O Policies and indemnification rights under the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws .

(b) Disability. In the event that Employee becomes physically or mentally disabled such that he is unable to perform his duties for a period of three (3) consecutive months as determined by a medical professional (“Disability”), the Company may terminate Employee’s employment, unless otherwise prohibited by law. In the event of termination due to Disability, Employee shall be paid, on Employee’s first regular payday following the Termination Date, a lump sum payment equivalent to the Accrued Benefits. In addition, (i) the Company will pay Employee a cash lump sum in an amount equal to half of Employee’s Base Salary; (ii) the Company shall pay any unpaid Annual Bonus with respect to the calendar year ended prior to the termination of Employee’s employment and a pro rata Annual Bonus (based upon his target Annual Bonus) for the year in which the termination of employment occurs; (iii) the Company shall fully accelerate vesting of any and all unvested

 

- 9 -

stock options, restricted stock units and restricted stock grants held by Employee; and (iv) the Company shall continue the Employee’s right to indemnification and coverage under the D&O Policies and indemnification rights under the applicable provisions of the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.

6.7 Board Action. The Company agrees to take all actions required by the Board or otherwise to accelerate Employee’s unvested stock options, restricted stock units and restricted stock grants as required by Sections 6.2 or 6.6.

6.8 Adjustment of Payments and Benefits. Notwithstanding any provision of this Agreement to the contrary, if any payment or benefit to be paid or provided under this Agreement or otherwise would be an “Excess Parachute Payment,” within the meaning of Section 280G of the Code, or any successor provision thereto, but for the application of this sentence, then the payments and benefits to be paid or provided hereunder shall be reduced to the minimum extent necessary (but in no event to less than zero) so that no portion of any such payment or benefit, as so reduced, constitutes an Excess Parachute Payment; provided, however, that the foregoing reduction shall be made only if and to the extent that such reduction would result in an increase in the aggregate payments and benefits to be provided, determined on an after-tax basis (taking into account the excise tax imposed pursuant to Section 4999 of the Code, or any successor provision thereto, any tax imposed by any comparable provision of state law, and any applicable federal, state and local income taxes). The determination of whether any reduction in such payments or benefits to be provided hereunder is required pursuant to the preceding sentence shall be made at the expense of the Company, if requested by Employee or the Company, by the Company’s independent accountants. The fact that Employee’s right to payments or benefits may be reduced by reason of the limitations contained in this Section 6.8 shall not of itself limit or otherwise affect any other rights of Employee under this Agreement. In the event that any payment or benefit intended to be provided hereunder is required to be reduced pursuant to this Section 6.8, such payments or benefits will be reduced in the following order (to the extent applicable): (a) the lump sum severance payment described in Section 6.2(a)(i); (b) the lump sum severance payment described in Section 6.2(b)(i) (multiple of Base Salary); (c) the lump sum severance payment described in Section 6.2(b)(ii) (multiple of target Annual Bonus); (d) the lump sum severance payment described in Section 6.2(c)(i) (multiple of Base Salary); (e) the lump sum severance payment described in Section 6.2(c)(ii) (multiple of target Annual Bonus); (f) the benefits described in Section 6.2(d)(ii) (reimbursement for certain outplacement services and moving expenses); (g) the benefits described in Section 6.2(d)(iii) (reimbursement for cost of continued medical and dental benefits); (h) the benefits described in Section 6.2(d)(iv) (unpaid Annual Bonus with respect to year prior to year of termination); and (i) the benefits described in Section 6.2(c)(v) (accelerated vesting of equity awards).

 

- 10 -

7. Agreement Not to Compete.

7.1 No Employment with, or Connection to, Competitor. Employee agrees that, during the term of employment with the Company and for a period of nine (9) months following the Termination Date, Employee will not, without securing the prior written permission of the Company:

(a) be employed by, act as an agent for, or consult with or otherwise perform services for, a Competitor (as defined below); or

(b) own any equity interest in, manage or participate in the management (as an officer, director, partner, member or otherwise) of, or be connected in any other manner with, a Competitor, except that this section shall not restrict Employee from owning less than one percent (1%) of the equity interests of any publicly held entity.

7.2 Nonsolicitation of Company Employees and Customers. Employee agrees that for a period of one (1) year following the Termination Date, Employee will not, without securing the prior written permission of the Company, induce or attempt to induce any Employee, officer, director, agent, independent contractor, consultant, customer, strategic partner, licensor, licensee, supplier or other service provider of the Company to terminate a relationship with, cease providing services or products to, or purchasing products or services from, the Company.

7.3 Definition of Competitor. The term “Competitor” as used in this Agreement means any individual or entity that is directly or indirectly engaged in the development and/or commercialization in the United States of one or more ex vivo cellular immunotherapies for the therapeutic treatment of prostate cancer (or any other cancer at which the Company’s immunotherapies are targeted as of the Termination Date), which ex vivo cellular immunotherapies generate twenty percent (20%) or more of either the annual gross revenue or worldwide operating expense of such Competitor in the United States. The term “Competitor” also includes an individual or entity that is preparing to directly or indirectly engage in the development and/or commercialization in the United States of such ex vivo cellular immunotherapies, if such ex vivo immunotherapies are anticipated to generate twenty (20%) or more of either the annual gross revenue or annual operating expense of such Competitor in the United States during the first calendar year of development and/or commercialization.

7.4 Reasonableness of Restrictions. The Company and Employee agree that, in light of all of the facts and circumstances relating to the relationship that exists and is expected to exist between the Company and Employee, these restrictions (including, but not limited to, the scope of the restricted activities, the duration of the restrictions, and the geographic extent of the restrictions) are fair and reasonably necessary for the protection of the goodwill and other protectable interests of the Company. If a court or arbitrator of competent jurisdiction declines to enforce any of these restrictions, the Company and Employee agree that the restrictions shall be enforceable to the maximum extent allowed by law.

8. Legal Fees and Expenses. Within thirty (30) days following receipt of an invoice for services performed, the Company shall reimburse Employee for all reasonable, appropriately documented attorneys’ fees incurred in connection with the negotiation and execution of this Agreement, provided, however, that the amount reimbursed under this sentence shall not exceed fifteen thousand dollars ($15,000). Unless prohibited by law, if Employee prevails on at least one substantive issue in seeking to enforce the Company’s obligations under this Agreement, the Company shall pay and be solely responsible for any and all costs and expenses (including attorneys’ fees) incurred by Employee in connection with Employee’s action to enforce the Company’s obligations under this Agreement. The Company shall pay directly or

 

- 11 -

reimburse Employee for any and all such costs and expenses within sixty (60) calendar days following the presentation by Employee or by counsel selected from time to time by Employee of a statement or statements prepared by Employee or by such counsel of the amount of such costs and expenses. The Company shall also pay to Employee interest (calculated at the base rate from time to time in effect at Bank of America, compounded monthly) on any payments or benefits that are paid or provided to Employee later than the date on which due under the terms of this Agreement.

In order to comply with Section 409A of the Code, (a) in no event will the payments by the Company under Section 8 of this Agreement be made later than the end of the calendar year next following the calendar year in which such fees and expenses were incurred; Employee shall be required to submit an invoice for such fees and expenses at least 10 days before the end of the calendar year next following the calendar year in which such fees and expenses were incurred; (b) the amount of such legal fees and expenses that the Company is obligated to pay in any given calendar year will not affect the legal fees and expenses that the Company is obligated to pay in any other calendar year; (c) the Company’s obligation to pay Employee’s legal fees will terminate on the fifth anniversary of the termination of this Agreement; and (d) Employee’s right to have the Company pay such legal fees and expenses may not be liquidated or exchanged for any other benefit.

9. General Provisions.

9.1 Successors and Assigns. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company. Employee shall not be entitled to assign any of Employee’s rights or obligations under this Agreement.

9.2 Waiver. Either party’s failure to enforce any provision of this Agreement shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Agreement.

9.3 Severability. In the event any provision of this Agreement is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefits contemplated in this Agreement to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected.

9.4 Interpretation; Construction. The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. Both parties have participated in the negotiation of this Agreement. Therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.

9.5 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (a) by personal

 

- 12 -

delivery when delivered personally; (b) by overnight courier upon written verification of receipt; (c) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth below, or such other address as either party may specify in writing.

9.6 Survival. Section 6 (“Separation of Employee’s Employment”), Section 7 (“Confidentiality; Agreement Not to Compete”), Section 8 (“Legal Fees and Expenses”), and Section 9 (“General Provisions”) of this Agreement shall survive Employee’s employment by the Company.

9.7 Entire Agreement. This Agreement, the Company’s equity compensation plan and documents reflecting restricted stock granted to Employee, the Proprietary Information and Inventions Agreement entered into by Employee at the commencement of employment with the Company, and the Indemnity Agreement entered into by the Company and Employee, if any, constitute the entire agreement between the parties relating to this subject matter and supersede all prior or simultaneous representations, discussions, negotiations, and agreements, whether written or oral. This Agreement may be amended or modified only with the written consent of Employee and a duly authorized officer of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.

9.8 Injunctive Relief. Notwithstanding the foregoing, any action brought by the Company under this Agreement seeking a temporary restraining order, temporary and/or permanent injunction and/or decree of specific performance of the terms of this Agreement may be brought in any court of competent jurisdiction. The Company shall not be required to post a bond as a condition for the granting of such relief.

9.9 Governing Law and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New Jersey as though made and to be fully performed in that State. Venue for any action arising from this Agreement shall be exclusively in New Jersey.

9.10 Arbitration.

(a) Employee and the Company agree that if a dispute arises concerning or relating to Employee’s employment with the Company, or the termination of Employee’s employment, such dispute shall be submitted to binding arbitration under the rules of the American Arbitration Association regarding resolution of employment disputes in effect at the time such dispute arises. The arbitration shall take place in New Jersey, before a single experienced arbitrator licensed to practice law in New Jersey and selected in accordance with the American Arbitration Association rules and procedures. Except as provided below, Employee and the Company agree that this arbitration procedure will be the exclusive means of redress for any disputes relating to or arising from Employee’s employment with the Company or his termination, including disputes over rights provided by federal, state, or local statutes, regulations, ordinances, and common law, including all laws that prohibit discrimination based on any protected classification. The parties expressly waive the right to a jury trial, and agree

 

- 13 -

that the arbitrator’s award shall be final and binding on both parties, and shall not be appealable. The arbitrator shall have discretion to award monetary and other damages, and any other relief that the arbitrator deems appropriate and is allowed by law taking into consideration Section 8 of this Agreement.

(b) The Company and Employee agree that the sole dispute that is excepted from Section 9.10 is an action seeking injunctive relief from a court of competent jurisdiction regarding enforcement and application of Section 7 of this Agreement, which action may be brought in addition to, or in place of, an arbitration proceeding in accordance with Section 9.10.

9.11 Withholding. All payments and benefits made to Employee hereunder will be subject to any payroll and withholding deductions required by applicable law.

9.12 Compliance with Section 409A of the Code.

(a) To the extent applicable, it is intended that the compensation arrangements under this Agreement be in full compliance with Section 409A of the Code (it being understood that certain compensation arrangements under this Agreement are intended not to be subject to Section 409A of the Code). The Agreement shall be construed, to the maximum extent permitted, in a manner to give effect to such intention. Notwithstanding anything in this Agreement to the contrary, distributions upon termination of Employee’s employment may only be made upon Employee’s “separation from service” with the Company (as determined in accordance with Section 409A of the Code). Employee acknowledges that Employee has been advised to obtain independent legal, tax or other counsel in connection with Section 409A of the Code.

(b) Compliance with Section 409A of the Code. Notwithstanding any provisions of this Agreement to the contrary, if Employee is a “specified employee” (within the meaning of Section 409A of the Code and determined pursuant to policies adopted by the Company) at the time of Employee’s separation from service and if any portion of the payments or benefits to be received by Employee upon separation from service would be considered deferred compensation under Section 409A of the Code (“Nonqualified Deferred Compensation”), amounts that would otherwise be payable pursuant to this Agreement during the six-month period immediately following Employee’s separation from service that constitute Nonqualified Deferred Compensation and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Employee’s separation from service that constitute Nonqualified Deferred Compensation will instead be paid or made available on the earlier of (i) the first business day of the seventh month following the date of Employee’s separation from service and (ii) Employee’s death.

(c) With respect to any amount of expenses eligible for reimbursement under this Agreement, such expenses will be reimbursed by the Company within thirty (30) calendar days following the date on which the Company receives the applicable invoice from Employee in accordance with the Company’s expense reimbursement policies, but in no event later than the last day of Employee’s taxable year following the taxable year in which Employee incurs the related expenses. In no event will the reimbursements or in-kind benefits to be provided by the Company in one taxable year affect the amount of reimbursements of in-kind benefits to be provided in any other taxable year, nor will Employee’s right to reimbursement or in-kind benefits be subject to liquidation or exchange for another benefit.

 

- 14 -

(d) Each payment under this Agreement shall be regarded as a “separate payment” and not of a series of payments for purposes of Section 409A of the Code.

THE PARTIES TO THIS AGREEMENT HAVE READ THIS AGREEMENT AND FULLY UNDERSTAND EACH AND EVERY PROVISION.

 

W. THOMAS AMICK

/s/ W. Thomas Amick

DENDREON CORPORATION
By:  

/s/ Robert Crotty

Its:
Address:
200 Crossing Boulevard
Bridgewater, NJ 08807

 

- 15 -



Exhibit 99.1

 

 

LOGO

Dendreon Names W. Thomas Amick President and Chief Executive Officer

SEATTLE, JULY 30, 2014 – Dendreon Corporation (Nasdaq: DNDN) today announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the Company’s board of directors. Mr. Amick succeeds John H. Johnson, who previously announced his plans to step down as president and chief executive officer for personal reasons. Mr. Johnson will work with Mr. Amick through August 15, 2014 to ensure a smooth transition.

Mr. Amick brings to Dendreon significant experience within the pharmaceutical and life sciences industry. Most recently from 2010 to 2012, he served as chairman and chief executive officer of Discovery Labs, a specialty biotechnology company. Under his leadership, Discovery Labs was granted approval for Surfaxin, the first synthetic lung surfactant approved for use in premature infants. Prior to that, Mr. Amick enjoyed a highly successful 30-year career with Johnson & Johnson where, as vice president of the Ortho Biotech Oncology Franchise, he launched Procrit® (epoetin alfa) and built J&J’s oncology franchise into a multi-billion dollar operation, making Procrit the most successful product in J&J history at the time. Mr. Amick also previously held positions as president of Ortho Biotech Europe, president of Janssen-Ortho Canada, and vice president of J&J Development Corporation (the venture capital division of J&J).

“Tom’s appointment is the result of a thorough search process,” said Douglas G. Watson, chairman of the board. “We believe that Tom’s leadership experience and oncology product expertise make him an excellent fit for Dendreon.”

“I have a great passion and respect for Dendreon’s mission of transforming the lives of patients through the discovery, development and commercialization of innovative cancer treatments,” said Mr. Amick. “I believe that PROVENGE is a unique immunotherapy treatment and look forward to working with the Dendreon team.”

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Dendreon’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, whether we are able to pay off or refinance our indebtedness, the dilution or other effects resulting from capital raising or debt restructuring transactions, our inability to achieve and sustain commercial success for PROVENGE; the identification of efficacy, safety or other issues with PROVENGE; a slower than anticipated adoption by treating physicians of PROVENGE for the treatment of patients with advanced prostate cancer for a variety of reasons, including competing therapies, instability in our sales force, the risk that we cannot replace vacant sales positions on a prompt basis, perceived difficulties in the treatment process, delays in obtaining reimbursement or for other reasons; any promotional limitations imposed by the FDA or the EU on our ability to commercialize and market PROVENGE; unexpected difficulties and costs associated with the rapid expansion of our commercial operations to support the commercial launch of PROVENGE; the impact of competing therapies on sales of PROVENGE, the failure to achieve reimbursement approvals in Europe, manufacturing or quality difficulties, disruptions or delays and other factors discussed in the “Risk Factors” section of Dendreon’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. All forward-looking statements are qualified in their entirety by this cautionary statement. Dendreon is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT:

Dendreon Corporation

Corporate Communications

Lindsay Rocco, 862-596-1304

media@dendreon.com